Cargando…
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
BACKGROUND AND AIMS: Tenofovir disoproxil fumarate (TDF) demonstrated potent and sustainable antiviral efficacy and a good safety profile in patients with chronic hepatitis B (CHB) in controlled clinical trials. Real-world data are important to confirm effectiveness and safety data in patient popula...
Autores principales: | Marcellin, Patrick, Zoulim, Fabien, Hézode, Christophe, Causse, Xavier, Roche, Bruno, Truchi, Régine, Pauwels, Arnaud, Ouzan, Denis, Dumortier, Jérôme, Pageaux, Georges-Philippe, Bourlière, Marc, Riachi, Ghassan, Zarski, Jean-Pierre, Cadranel, Jean-François, Tilliet, Valérie, Stern, Christiane, Pétour, Pascal, Libert, Olivier, Consoli, Silla M., Larrey, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020114/ https://www.ncbi.nlm.nih.gov/pubmed/26821154 http://dx.doi.org/10.1007/s10620-015-4027-8 |
Ejemplares similares
-
Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021) -
Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015) -
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019) -
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022) -
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil
Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)